RefleXion Medical Seeks FDA Clearance for New Tumor-Tracking Radiotherapy Technology

RefleXion Medical has filed for FDA clearance of Anchor Point Tracking, a tumor-targeting technology for its new X2 radiotherapy platform.

RefleXion Medical has submitted a 510(k) premarket notification to the FDA seeking clearance for a new tumor tracking system called Anchor Point Tracking, designed for use with the company's next-generation X2 platform. The filing is a regulatory step that, if cleared, would allow the technology to be marketed and used clinically in the United States. RefleXion describes itself as an external beam theranostic oncology company — a field that combines cancer imaging and therapy. Anchor Point Tracking is positioned as an advancement in the company's existing SCINTIX autonomous radiotherapy approach, which aims to guide radiation delivery in real time based on tumor location.

Why it matters

If cleared, the technology could improve the precision of radiation delivery by tracking tumors during treatment, potentially reducing damage to surrounding healthy tissue. It represents a step toward more autonomous, biology-guided radiotherapy systems in cancer care.

What's next

The FDA will review the 510(k) submission to determine whether Anchor Point Tracking meets the criteria for clearance.

Key facts

• RefleXion Medical submitted a 510(k) premarket notification to the FDA for Anchor Point Tracking
• Anchor Point Tracking is designed for use with the RefleXion X2 platform, described as next-generation
• The technology is intended as a tumor tracking system for autonomous radiotherapy
• RefleXion describes itself as an external beam theranostic oncology company
• The submission seeks FDA clearance, not approval — a regulatory pathway for devices deemed substantially equivalent to existing cleared devices

Bias & framing notes

All three sources ran identical headlines, and two of the three sources were paywalled with no accessible reporting. The single available source appears to be a company press release republished verbatim, meaning all information comes from one interested party with no independent journalism or verification.

NewsClear — neutral news & congressional tracking · Bill of the Week